Nexsen (ASX:NXN) has achieved a regulatory and operational milestone following the award of a HK$6 million IGNITE Grant to its subsidiary, Nexsen Hong Kong.
Issued by the Hong Kong Science and Technology Parks, this non-dilutive funding is earmarked for the clinical validation and manufacturing scale-up of StrepSure, the company's proprietary point-of-care diagnostic test for Group B Streptococcus.
The capital infusion positions Hong Kong as a primary manufacturing and distribution hub, providing Nexsen with a gateway to a massive regional market characterised by over 47 million annual births.
Managing Director Mark Muzzin noted that the grant serves as a powerful validation of the company's strategy to establish in-region capabilities.
By leveraging established local hospital networks, Nexsen intends to fast-track clinical validation studies and support early adoption in a market where GBS prevalence is estimated at 21.5%.
Beyond immediate clinical testing, the funding will be applied to tailoring device performance and workflow requirements specifically for Asia-Pacific healthcare environments.
The initiative is designed to generate critical real-world performance data, transitioning StrepSure toward commercial readiness while maintaining a capital-efficient, non-dilutive structure for shareholders.